Bio Light Israeli Life Sciences Investments Ltd., which went public in December 2005 at a value of $10 million, announced on Sunday it was planning a second offering on the Tel Aviv Stock Exchange.
Bio Light, which increased its market value to $15m. since floatation, also reported developments at three of its four subsidiaries.
Obcure Ltd., which has discovered a treatment for obesity, has obtained US Food and Drug Administration approval to bypass Phase I safety trials and jump directly to Phase II clinical trials; Allergica Ltd., which is developing an allergy treatment, has hired Yaffa Beck as chairperson; and Zetiq Technologies Ltd. will launch its first preparations for identifying cancerous cells in a few months.
Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>